Chinghai Hai Kao from 1933 Camargue Dr, Zionsville, IN 46077, age 66, Phone: (317)7333746

Us Patents

Production Of Adenoviral Vectors Using Serum-Free Suspension Cell Culture In A Hollow Fiber System
view source
US Patent:

6342384, Jan 29, 2002
Filed:

Nov 17, 1998
Appl. No.:

09/193134
Inventors:

Leland W. K. Chung - Lovingston VA
Thomas A. Gardner - Charlottesville VA
Chinghai Kao - Charlottesville VA
Assignee:

The University of VA Patent Foundation - Charlottesville VA
International Classification:

C12N 702
US Classification:

4352351, 435239
Abstract:

The present invention relates to methods for the production of high titers of serum-free lytic viruses in a hollow fiber cartridge capillary system. The invention further relates to methods of infecting target cells at high multiplicity and for producing high concentrations of transduced target cells.

Utilization Of Osteocalcin Promoter To Deliver Therapeutic Genes To Tumors
view source
US Patent:

6596534, Jul 22, 2003
Filed:

Mar 23, 2000
Appl. No.:

09/534414
Inventors:

Leland W. K. Chung - Lovingston VA
Chinghai Kao - Charlottesville VA
Robert A. Sikes - Charlottesville VA
Jun Cheon - Anam-Dong, KR
Assignee:

The University of Virginia Patent Foundation - Charlottesville VA
International Classification:

A01N 6300
US Classification:

4353201, 424 932, 424 936, 514 44, 435 691
Abstract:

A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

Bone Cancer Therapy
view source
US Patent:

20010038834, Nov 8, 2001
Filed:

Jun 24, 1998
Appl. No.:

09/103807
Inventors:

GARY BALIAN - CHARLOTTESVILLE VA, US
QUANJUN CUI - CHARLOTTESVILLE VA, US
LELAND W.K. CHUNG - LOVINGSTON VA, US
CHINGHAI KAO - CHARLOTTESVILLE VA, US
THOMAS A. GARDNER - CHARLOTTESVILLE VA, US
International Classification:

A61K048/00
C12N005/06
A61K039/00
US Classification:

424/093100, 424/277100, 435/325000
Abstract:

Homing bone marrow cells deposited at ATTC CRL-12424 can be transfected with a toxic gene which expresses a compound which alone, or in the company of a triggering agent, kills neighboring cancer cells in the bone marrow of a patient receiving the therapy. Toxic genes include cytotoxin such as thymidine kinase, immune stimulating compounds such as interleuken-2 and radiation repair inhibitors, such as Ku protein. The transfected cells can be administered directly to the site of the tumor or systemically, or regionally, intramedullary (into the marrow) through intravascular administration. The latter alternative permits the delivery of very high doses of the effective agent.

Production Of Adenoviral Vectors Using Serum-Free Suspension Cell Culture In A Hollow Fiber System
view source
US Patent:

20020052041, May 2, 2002
Filed:

Sep 6, 2001
Appl. No.:

09/947115
Inventors:

Leland Chung - Lovingston VA, US
Thomas Gardner - Charlottesville VA, US
Chinghai Kao - Charlottesville VA, US
Assignee:

University of Virginia Patent Foundation.
International Classification:

C12N007/00
US Classification:

435/235100
Abstract:

The present invention relates to methods for the production of high titers of serum-free lytic viruses in a hollow fiber cartridge capillary system. The invention further relates to methods of infecting target cells at high multiplicity and for producing high concentrations of transduced target cells.

Gene Expression Directed By A Super-Psa Promoter
view source
US Patent:

20030078224, Apr 24, 2003
Filed:

Apr 24, 2002
Appl. No.:

10/128670
Inventors:

Leland Chung - Atlanta GA, US
Fan Yeung - Charlottesville VA, US
Chinghai Kao - Indianapolis IN, US
International Classification:

A61K048/00
C12Q001/68
A01K067/00
C07H021/04
C12P021/02
C12N005/06
US Classification:

514/044000, 800/008000, 435/006000, 435/069300, 435/320100, 435/325000, 536/023200
Abstract:

The present invention provides methods and compositions for the delivery and expression of therapeutic genes for treating prostate and non-prostate tumors in a gene therapy setting with therapeutic genes driven by a super PSA promoter. This approach enhances the capability of increasing the size of therapeutic gene inserts and maintaining specificity and efficiency of genes expression. This form of gene therapy strategy can be applied either alone or in combination with other adjuvant therapies or used in combination with various gene therapy strategies to achieve the maximum effect in cancer treatment, and in normal and benign tissues to enhance therapeutic gains.

Prostate-Specific Chimeric Enhancers And Methods Of Use Thereof
view source
US Patent:

20030235874, Dec 25, 2003
Filed:

May 8, 2003
Appl. No.:

10/431791
Inventors:

Chinghai Kao - Zionsville IN, US
Sang-Jin Lee - Indianapolis IN, US
Hong-Sup Kim - ChungJu, KR
KangRyul Lee - Seoul, KR
Rong Yu - Chengdu, CN
International Classification:

G01N033/574
C07H021/04
C12P021/04
C12N009/02
C12N009/10
C12N009/12
C12N009/16
C12N009/40
C12N005/06
US Classification:

435/007230, 435/069700, 435/320100, 435/189000, 435/193000, 435/194000, 435/196000, 435/208000, 530/350000, 536/023200
Abstract:

Compositions and methods are provided for the treatment of androgen-independent and androgen-dependent prostate carcinomas.

Compositions And Methods For Modulating Tumor Specific Expression
view source
US Patent:

20040038232, Feb 26, 2004
Filed:

Mar 31, 2003
Appl. No.:

10/296666
Inventors:

Thomas Gardner - Zionsville IN, US
Chinghai Kao - Indianapolis IN, US
Fan Yeung - Charlottesville VA, US
Lelend Chung - Atlanta GA, US
International Classification:

C12Q001/68
C07H021/04
C07K014/705
US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:

The present invention relates to promoters, enhancers and other regulatory elements that direct expression within tumor cells, comprising nucleotide sequences from the 5′ regulatory region, and transcriptionally active fragments thereof, that control expression of a renal cell carcinoma related protein, MN-CA9. Specifically provided are expression vectors, host cells and transgenic animals wherein an MN-CA9 regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous gene or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important in cancer development and/or progression. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of cancer development and/or progression. The invention further relates to compositions and methods for modulating expression of compounds within tumor cells, and to screening compounds that modulate expression within tumor cells. Methods for using the molecules and compounds identified by the screening assays for therapeutic treatments also are provided.

Osteocalcin Promoter-Based Toxic Gene Therapy For The Treatment Of Calcified Tumors And Tissues
view source
US Patent:

57729930, Jun 30, 1998
Filed:

Jan 21, 1997
Appl. No.:

8/785088
Inventors:

Leland W. K. Chung - Lovingston VA
Chinghai Kao - Charlottesville VA
Robert A. Sikes - Charlottesville VA
Jun Cheon - Sol, KR
Assignee:

The University of Virginia Patent Foundation - Charlottesville VA
International Classification:

A61K 4800
A01N 6300
C12P 2104
C12N 1500
US Classification:

424 936
Abstract:

A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, to Ad-OC-TK resulted in the induction of osteoblast-specific cell death in vitro. The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.